Research

The goal of this study is to explore how discontinuing ocrelizumab may affect long-term remission in early MS.

We are currently recruiting participants who have recently been diagnosed with relapsing MS to determine whether people can remain in remission after discontinuing ocrelizumab.

This study aims to better understand MS by looking at cell-free DNA — tiny genetic fragments in blood that give clues about what is happening in the body.

We are looking for samples from patients with MS and volunteers without MS. This is a one-time study visit that includes a single blood draw.

The goal of this study is to understand the safety and tolerability of ublituximab (Briumvi) in people with early relapsing MS. We also want to measure changes in a blood biomarker (neurofilament light chain) before and after treatment.

This study aims to create a retrospective registry of patients with NMO spectrum disorder seen at Northwestern. This registry will allow us to better understand disease progression, physicians' clinical decision-making and its impact on patients, and the effects of the types of medications and treatments used.

This study examines the use of Ocrevus Zunovo (OZ), a recently approved subcutaneous (under-the-skin) form of ocrelizumab for people with relapsing-remitting multiple sclerosis and primary progressive multiple sclerosis. Researchers will follow participants for one year to better understand treatment satisfaction, quality of life and long-term use of OZ.

The study will also gather perspectives from patients, caregivers, healthcare providers and insurance stakeholders to identify ways to improve access to high-efficiency MS therapies and reduce delays in treatment initiation.

We are enrolling individuals with MS who are being treated with Ocrevus and are either currently taking or planning to start a GLP-1 medication.

The study aims to better understand how GLP-1 medications may affect MS symptoms, energy, walking ability and overall quality of life.

This is a Stage IV clinical trial that focuses on collecting observational data on the Briumvi experience in real-world clinical practice to evaluate its effectiveness, safety and tolerability over the course of 96 weeks. This will be determined from patient questionnaires collected at each Briumvi infusion, treatment decisions, transition methodologies between therapies and clinical markers.

Electroencephalogram (EEG) is the primary diagnostic tool for epilepsy but remains inaccessible to most of the global population due to high equipment costs and limited trained personnel. This study evaluates the usability and diagnostic efficacy of the BrainCapture-1, a smartphone-connected EEG device enabling non-expert healthcare workers to perform clinically usable EEG recordings in low-resource settings.

This study will focus on capacity building for neuroimmunological diagnosis and management in the Republic of Guinea. This study evaluates low-cost diagnostic techniques for NMO, allowing our team to detect the aquaporin-4 antibody from small blood samples collected by the patient on filter paper and mailed to the processing laboratory for analysis.